TOP STORIES

• REGULATORY Four Ministers Map Out Basic Policy for Drug Pricing Revamp
  December 21, 2016

• REGULATORY Basic Policy for Drastic Reform of Drug Pricing System
  December 20, 2016

• BUSINESS Keytruda Gets NSCLC Nod Both in 1st-Line, 2nd-Line Settings
  December 20, 2016

• ACADEMIA New Lung Cancer Guidelines to Give Keytruda Grade A Recommendation as First-Line Treatment
  December 19, 2016

• BUSINESS Fujifilm to Acquire Takeda’s Reagent Unit for 155 Billion Yen
  December 16, 2016

• BUSINESS Nippon Kayaku Introduces “MSLs” to Strengthen Detailing for Oncology Generics, Biosimilars, and Products in Development
  December 16, 2016

• ORGANIZATION JMA Wants Adjustment Rate as High as 5%: Yokokura
  December 15, 2016

• REGULATORY PD-L1 Expression Testing Won’t Be a Must for Opdivo, but Clarification Needed: Chuikyo
  December 15, 2016

• REGULATORY MHLW Drafts Optimal Use Guidelines for Opdivo in NSCLC
  December 14, 2016

• REGULATORY Survey Method, Product Scope for Annual Revisions to Be Discussed in 2017
  December 14, 2016

• BUSINESS Aspen Japan Starting on Right Foot on AG Biz: GSK Japan President
  December 13, 2016

• REGULATORY Chuikyo Reps, Distributors Fret Market Prices Will Be Kept High with Annual Revisions
  December 12, 2016

• REGULATORY (Update) “2%” Adjustment Rate Should Be Made a Discussion Point for Annual Revisions: Chuikyo Rep
  December 12, 2016

• REGULATORY Govt Eyes “Bailout Measures” for Products with Small NHI-Market Price Gaps in Annual Revision Plan
  December 9, 2016

• REGULATORY Shiozaki, Govt Panel Agree on Annual Price Reviews, but Scope of Drugs Still Unclear
  December 8, 2016

• BUSINESS Mitsubishi Tanabe Fending Off Inroads from Biosimilars through Add’l Indications for Remicade
  December 8, 2016

• REGULATORY LDP Tax Panel OKs Refit of R&D Tax Credit System in FY2017
  December 7, 2016

• BUSINESS Acquisition of Long-Listed Drugs to Promote Generic Sales; Sales Target of 50 Billion Yen “in Range”: Kyowa Pharm
  December 7, 2016

• ORGANIZATION Drug Pricing Policy Can’t Be Defined in 2-3 Weeks: PhRMA Exec
  December 6, 2016

• BUSINESS Chugai to Enter Hemophilia Field with Emicizumab; Peak Sales Could Top 200 Billion Yen
  December 6, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 159
• 160
• 161
• 162
• 163
• 164
• 165
• 166
• 167
• …
• Next ›
• 最終 »